Meetings - The ASCO Post

Lung Cancer Progression-Free Survival With Immunotherapy Varies Significantly by Tumor-Mutation Subtype, Real-World Data Show

A real-world study of single-agent immune checkpoint inhibitors in driver-mutated non–small cell lung cancer (NSCLC) has demonstrated significant variation in progression-free survival between mutatio...

Immunotherapy

By Chase Doyle / November 25, 2020 / IASLC 2020 North America Conference on Lung Cancer

Use of Pembrolizumab in Advanced Pleural Mesothelioma: Results From KEYNOTE-158

The largest single-arm trial evaluating pembrolizumab in relapsed malignant pleural mesothelioma has demonstrated an “impressive” duration of response, according to a presentation during the virtual e...

Lung Cancer

Immunotherapy

By Chase Doyle / November 25, 2020 / IASLC 2020 North America Conference on Lung Cancer

Nivolumab Plus Ipilimumab in First-Line NSCLC: Two New Indications, Many More Questions

In May 2020, the combination of nivolumab and ipilimumab was approved by the U.S. Food and Drug Administration (FDA) for two separate indications in the first-line setting of advanced non–small cell ...

IASLC 2020 North America Conference on Lung Cancer

Lung Cancer Progression-Free Survival With Immunotherapy Varies Significantly by Tumor-Mutation Subtype, Real-World Data Show

Use of Pembrolizumab in Advanced Pleural Mesothelioma: Results From KEYNOTE-158

Nivolumab Plus Ipilimumab in First-Line NSCLC: Two New Indications, Many More Questions

Firefighters May Be Exposed to Chemicals Associated With Breast Cancer

FDA Grants Accelerated Approval to Zanidatamab-hrii for Previously Treated Unresectable or Metastatic HER2-Positive Biliary Tract Cancer

Novel EGFR Inhibitor Firmonertinib Shows Activity in Rare Subtype of NSCLC

Outcomes of Immune Checkpoint Inhibitor Treatment for Cancer in Black vs White Patients in the U.S. VHA System

Pooled Analysis of Long-Term Outcomes With Nivolumab With or Without Ipilimumab in Advanced Melanoma